

## CLAIMS

1. A fusion polypeptide which comprises a polypeptide having a human granulocyte colony stimulating factor activity and a polypeptide having a platelet growth factor activity.
2. A fusion polypeptide in which a polypeptide having a human granulocyte colony stimulating factor activity and a polypeptide having a platelet growth factor activity are fused via a spacer peptide.
3. The fusion polypeptide according to claim 1 wherein the fusion polypeptide is a polypeptide which contains an amino acid sequence selected from the amino acid sequences shown in Sequence ID Nos. 1, 2, 3, 4, 5 and 6.
4. A fusion polypeptide in which one or more amino acids are added, deleted or substituted in the amino acid sequence of the fusion polypeptide disclosed in claim 1, 2 or 3, and which has a human granulocyte colony stimulating factor activity and a platelet growth factor activity.
5. A fusion polypeptide having a human granulocyte colony stimulating factor activity and a platelet growth factor activity in which at least one amino group of the fusion polypeptide disclosed in claim 1, 2, 3 or 4 is chemically modified with a polyalkylene glycol derivative.
6. The fusion polypeptide according to claim 5 wherein the polyalkylene glycol derivative is a polyethylene glycol derivative, a polypropylene glycol derivative or a polyoxyethylene-polyoxypropylene copolymer derivative.

7. A DNA which codes for the fusion polypeptide disclosed in claim 1, 2, 3 or 4.

8. The DNA according to claim 6 wherein the DNA is a DNA which contains a sequence selected from the DNA sequences shown in Sequence ID Nos. 4, 5 and 6.

9. An anemia-treating composition containing the fusion polypeptide disclosed in claim 1, 2, 3, 4 or 5 as an active ingredient.

add A2